Skip to main content
. 2024 Jan 2;15:14. doi: 10.1038/s41467-023-44514-2

Fig. 3. Radiographic Progression-Free Survival and Overall Survival Estimates of Patients with mCRPC Treated with BAT in Combination with Nivolumab.

Fig. 3

Kaplan-Meier curves of A radiographic progression-free survival (rPFS) and B overall survival (OS) are shown. The median rPFS was estimated at 5.6 months (95% Confidence interval: 5.4–6.8 months). The median OS was estimated at 24.4 months. (95% Confidence interval: 17.6 – 31.1 months). The shaded area represents 95% confidence region.